JP2020534360A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534360A5 JP2020534360A5 JP2020537292A JP2020537292A JP2020534360A5 JP 2020534360 A5 JP2020534360 A5 JP 2020534360A5 JP 2020537292 A JP2020537292 A JP 2020537292A JP 2020537292 A JP2020537292 A JP 2020537292A JP 2020534360 A5 JP2020534360 A5 JP 2020534360A5
- Authority
- JP
- Japan
- Prior art keywords
- methylquinoline
- cyclopropane
- carboxamide
- sulfonyl
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- -1 Propane-2-yl Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
Claims (2)
- １−｛５−エチル−２−［（プロパン−２−イル）オキシ］ピリジン−３−イル｝−Ｎ−（２−メチルキノリン−５−スルホニル）シクロプロパン−１−カルボキサミド。
- １−｛５−エチル−２−［（プロパン−２−イル）オキシ］ピリジン−３−イル｝−Ｎ−（２−メチルキノリン−５−スルホニル）シクロプロパン−１−カルボキサミド又はその薬学的に許容される塩。
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021156375A JP7064073B2 (ja) | 2017-09-14 | 2021-09-27 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
| JP2021156376A JP7064074B2 (ja) | 2017-09-14 | 2021-09-27 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
| JP2022007648A JP2022062093A (ja) | 2017-09-14 | 2022-01-21 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558430P | 2017-09-14 | 2017-09-14 | |
| US62/558,430 | 2017-09-14 | ||
| US201762608846P | 2017-12-21 | 2017-12-21 | |
| US62/608,846 | 2017-12-21 | ||
| PCT/IB2018/057020 WO2019053634A1 (en) | 2017-09-14 | 2018-09-13 | MODULATORS OF THE TRANSMEMBRANE CONDUCTANCE REGULATORY PROTEIN OF CYSTIC FIBROSIS AND METHODS OF USE |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021156375A Division JP7064073B2 (ja) | 2017-09-14 | 2021-09-27 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
| JP2021156376A Division JP7064074B2 (ja) | 2017-09-14 | 2021-09-27 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
| JP2022007648A Division JP2022062093A (ja) | 2017-09-14 | 2022-01-21 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020534360A JP2020534360A (ja) | 2020-11-26 |
| JP2020534360A5 true JP2020534360A5 (ja) | 2021-10-21 |
| JP7064072B2 JP7064072B2 (ja) | 2022-05-10 |
Family
ID=63713961
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020537292A Active JP7064072B2 (ja) | 2017-09-14 | 2018-09-13 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
| JP2021156375A Active JP7064073B2 (ja) | 2017-09-14 | 2021-09-27 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
| JP2021156376A Active JP7064074B2 (ja) | 2017-09-14 | 2021-09-27 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
| JP2022007648A Pending JP2022062093A (ja) | 2017-09-14 | 2022-01-21 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021156375A Active JP7064073B2 (ja) | 2017-09-14 | 2021-09-27 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
| JP2021156376A Active JP7064074B2 (ja) | 2017-09-14 | 2021-09-27 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
| JP2022007648A Pending JP2022062093A (ja) | 2017-09-14 | 2022-01-21 | 嚢胞性線維症膜貫通コンダクタンス調節因子タンパク質のモジュレーター及び使用の方法 |
Country Status (33)
| Country | Link |
|---|---|
| US (6) | US10988454B2 (ja) |
| EP (4) | EP3736270B1 (ja) |
| JP (4) | JP7064072B2 (ja) |
| KR (1) | KR20200086661A (ja) |
| CN (1) | CN111954664A (ja) |
| AU (1) | AU2018332512A1 (ja) |
| BR (1) | BR112020005102A2 (ja) |
| CA (1) | CA3074945A1 (ja) |
| CL (1) | CL2020000664A1 (ja) |
| CO (1) | CO2020004249A2 (ja) |
| CR (1) | CR20200157A (ja) |
| CY (3) | CY1123761T1 (ja) |
| DK (3) | DK3736270T3 (ja) |
| EC (1) | ECSP20021913A (ja) |
| ES (3) | ES2881881T3 (ja) |
| HR (3) | HRP20210099T1 (ja) |
| HU (3) | HUE052873T2 (ja) |
| IL (1) | IL273163A (ja) |
| LT (3) | LT3681864T (ja) |
| MA (1) | MA50240B1 (ja) |
| MD (3) | MD3736267T2 (ja) |
| MX (1) | MX2020002806A (ja) |
| PE (1) | PE20210140A1 (ja) |
| PH (1) | PH12020500509A1 (ja) |
| PL (3) | PL3736267T3 (ja) |
| PT (3) | PT3736267T (ja) |
| RS (3) | RS62190B1 (ja) |
| RU (1) | RU2020113350A (ja) |
| SG (1) | SG11202002101RA (ja) |
| SI (3) | SI3681864T1 (ja) |
| UA (1) | UA125541C2 (ja) |
| WO (1) | WO2019053634A1 (ja) |
| ZA (1) | ZA202002363B (ja) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202140422A (zh) | 2014-10-06 | 2021-11-01 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| CN109803962B (zh) | 2016-09-30 | 2022-04-29 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物 |
| HUE052205T2 (hu) | 2016-12-09 | 2021-04-28 | Vertex Pharma | Cisztás fibrózis transzmembrán vezetõképesség szabályzó modulátora, gyógyszerészeti készítmények, kezelési eljárások és eljárás a modulátor elõállítására |
| US11253509B2 (en) | 2017-06-08 | 2022-02-22 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| BR112020000941A2 (pt) | 2017-07-17 | 2020-07-21 | Vertex Pharmaceuticals Incorporated | métodos de tratamento para fibrose cística |
| US11434201B2 (en) | 2017-08-02 | 2022-09-06 | Vertex Pharmaceuticals Incorporated | Processes for preparing pyrrolidine compounds |
| US10988454B2 (en) * | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
| AU2018350980B2 (en) | 2017-10-18 | 2023-02-23 | Incyte Corporation | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors |
| WO2019079760A1 (en) | 2017-10-19 | 2019-04-25 | Vertex Pharmaceuticals Incorporated | CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS |
| WO2019113476A2 (en) | 2017-12-08 | 2019-06-13 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| MX2020008268A (es) | 2018-02-15 | 2020-09-21 | Vertex Pharma | Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quistica, composiciones farmaceuticas de estos, su uso en el tratamiento de la fibrosis quistica y procesos para elaborarlos. |
| US11414439B2 (en) | 2018-04-13 | 2022-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
| WO2020128768A1 (en) * | 2018-12-18 | 2020-06-25 | Novartis Ag | N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide derivatives and their use in the treatment of a cftr mediated disease |
| BR112022002605A2 (pt) | 2019-08-14 | 2022-05-03 | Vertex Pharma | Formas cristalinas de moduladores de cftr |
| TW202115092A (zh) | 2019-08-14 | 2021-04-16 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| TW202120517A (zh) | 2019-08-14 | 2021-06-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| US20220213041A1 (en) * | 2021-01-06 | 2022-07-07 | AbbVie Global Enterprises Ltd. | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use |
| US20220211692A1 (en) * | 2021-01-06 | 2022-07-07 | AbbVie Global Enterprises Ltd. | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB602426A (en) * | 1945-10-24 | 1948-05-26 | Geigy Ag J R | Manufacture of aromatic acyl-sulphonamides |
| CA2427499A1 (en) * | 2000-10-10 | 2002-04-18 | Smithkline Beecham Corporation | Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-.gamma. binding agents |
| EP1765347A4 (en) | 2004-06-04 | 2008-10-01 | Univ California | COMPOUNDS WITH ION TRANSPORTER HEALING EFFECT BY MUTANT CFTR AND ITS USE |
| PL1773816T3 (pl) | 2004-06-24 | 2015-06-30 | Vertex Pharma | Modulatory transporterów posiadających kasetę wiążącą ATP |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| CN101715450B (zh) | 2006-11-03 | 2013-03-13 | 沃泰克斯药物股份有限公司 | 作为cftr调控剂的氮杂吲哚衍生物 |
| WO2008147952A1 (en) | 2007-05-25 | 2008-12-04 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| AU2008295476B2 (en) * | 2007-08-29 | 2013-08-01 | Merck Sharp & Dohme Corp. | 2, 3-Substituted Indole Derivatives for treating viral infections |
| CN102099351A (zh) * | 2007-11-16 | 2011-06-15 | 先灵公司 | 3-杂环取代的吲哚衍生物及其使用方法 |
| CN101939054B (zh) | 2007-12-10 | 2014-10-29 | 诺华股份有限公司 | 有机化合物 |
| EP2231671B1 (en) | 2007-12-13 | 2013-04-24 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| KR20100134063A (ko) * | 2008-03-25 | 2010-12-22 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 낭포성 섬유증 막투과 전도성 조절자의 수용성 소분자 억제제 |
| MX2011004374A (es) | 2008-10-23 | 2011-05-23 | Vertex Pharma | Formas solidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2-(trifluo rometil)fenil)-4-oxo-5-(trifluorometil)-1,4-dihidroquinolin-3-car boxamida. |
| SI2365972T1 (sl) * | 2008-11-06 | 2015-04-30 | Vertex Pharmaceuticals Incorporated | Modulatorji prenaĺ alcev z atp-vezavno kaseto |
| US8367660B2 (en) | 2008-12-30 | 2013-02-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN102458122A (zh) * | 2009-04-20 | 2012-05-16 | 人类健康研究所 | 含有哒嗪磺胺衍生物的化合物、组合物和方法 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| EP2624695B1 (en) | 2010-10-08 | 2015-09-23 | Nivalis Therapeutics, Inc. | Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| JP5886433B2 (ja) | 2011-09-16 | 2016-03-16 | ノバルティス アーゲー | 嚢胞性線維症処置のためのヘテロ環式化合物 |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| EP2755652B1 (en) | 2011-09-16 | 2021-06-02 | Novartis AG | N-substituted heterocyclyl carboxamides |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| US9127040B2 (en) | 2011-09-20 | 2015-09-08 | The University Of North Carolina At Chapel Hill | Regulation of sodium channels by PLUNC proteins |
| CN105531268B (zh) | 2013-05-07 | 2017-09-12 | 加拉佩格斯股份有限公司 | 用于治疗囊性纤维化的新化合物及其药物组合物 |
| EP3030568B1 (en) | 2013-08-08 | 2018-09-19 | Galapagos NV | Thieno[2,3-c]pyrans as cftr modulators |
| CN103484818A (zh) | 2013-09-25 | 2014-01-01 | 京东方科技集团股份有限公司 | 蒸镀方法、蒸镀装置和发光器件 |
| WO2015138909A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| CA2942387A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr actvity |
| KR102132215B1 (ko) | 2014-04-03 | 2020-07-09 | 삼성전자주식회사 | 자기 터널 접합 구조물 형성 방법 및 이를 이용한 자기 메모리 소자의 제조 방법 |
| TW202140422A (zh) * | 2014-10-06 | 2021-11-01 | 美商維泰克斯製藥公司 | 囊腫纖維化症跨膜傳導調節蛋白之調節劑 |
| EP3212189B1 (en) | 2014-10-31 | 2020-09-09 | AbbVie Overseas S.à r.l. | Substituted chromanes and method of use |
| MX2017005663A (es) | 2014-10-31 | 2018-03-01 | Abbvie Sarl | Tetrahidropiranos sustituidos y metodo de uso. |
| CA2988046A1 (en) | 2015-06-02 | 2016-12-08 | Abbvie S.A.R.L. | Substituted pyridines and method of use |
| US9840513B2 (en) | 2015-07-16 | 2017-12-12 | Abbvie S.Á.R.L. | Substituted tricyclics and method of use |
| PL3359541T3 (pl) | 2015-10-09 | 2021-01-11 | AbbVie Overseas S.à r.l. | N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA |
| CA3016303A1 (en) | 2016-04-26 | 2017-11-02 | Abbvie S.A.R.L. | Modulators of cystic fibrosis transmembrane conductance regulator protein |
| US10138227B2 (en) | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
| US9981910B2 (en) | 2016-10-07 | 2018-05-29 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
| US10399940B2 (en) | 2016-10-07 | 2019-09-03 | Abbvie S.Á.R.L. | Substituted pyrrolidines and methods of use |
| US10988454B2 (en) * | 2017-09-14 | 2021-04-27 | Abbvie Overseas S.À.R.L. | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use |
-
2018
- 2018-09-12 US US16/129,458 patent/US10988454B2/en active Active
- 2018-09-13 EP EP20183402.5A patent/EP3736270B1/en active Active
- 2018-09-13 EP EP21164249.1A patent/EP3865474A1/en not_active Withdrawn
- 2018-09-13 DK DK20183402.5T patent/DK3736270T3/da active
- 2018-09-13 PL PL20183405T patent/PL3736267T3/pl unknown
- 2018-09-13 MA MA50240A patent/MA50240B1/fr unknown
- 2018-09-13 RS RS20210975A patent/RS62190B1/sr unknown
- 2018-09-13 SI SI201830193T patent/SI3681864T1/sl unknown
- 2018-09-13 PL PL20183402T patent/PL3736270T3/pl unknown
- 2018-09-13 EP EP18779798.0A patent/EP3681864B1/en active Active
- 2018-09-13 BR BR112020005102-0A patent/BR112020005102A2/pt not_active Application Discontinuation
- 2018-09-13 EP EP20183405.8A patent/EP3736267B1/en active Active
- 2018-09-13 SI SI201830345T patent/SI3736270T1/sl unknown
- 2018-09-13 WO PCT/IB2018/057020 patent/WO2019053634A1/en unknown
- 2018-09-13 MD MDE20201160T patent/MD3736267T2/ro unknown
- 2018-09-13 RS RS20210973A patent/RS62185B1/sr unknown
- 2018-09-13 LT LTEP18779798.0T patent/LT3681864T/lt unknown
- 2018-09-13 HU HUE18779798A patent/HUE052873T2/hu unknown
- 2018-09-13 PT PT201834058T patent/PT3736267T/pt unknown
- 2018-09-13 SG SG11202002101RA patent/SG11202002101RA/en unknown
- 2018-09-13 MD MDE20200741T patent/MD3681864T2/ro unknown
- 2018-09-13 CN CN201880073855.3A patent/CN111954664A/zh active Pending
- 2018-09-13 AU AU2018332512A patent/AU2018332512A1/en not_active Abandoned
- 2018-09-13 PL PL18779798T patent/PL3681864T4/pl unknown
- 2018-09-13 ES ES20183402T patent/ES2881881T3/es active Active
- 2018-09-13 JP JP2020537292A patent/JP7064072B2/ja active Active
- 2018-09-13 KR KR1020207010867A patent/KR20200086661A/ko active IP Right Grant
- 2018-09-13 CR CR20200157A patent/CR20200157A/es unknown
- 2018-09-13 DK DK20183405.8T patent/DK3736267T3/da active
- 2018-09-13 HU HUE20183402A patent/HUE055241T2/hu unknown
- 2018-09-13 LT LTEP20183402.5T patent/LT3736270T/lt unknown
- 2018-09-13 PT PT201834025T patent/PT3736270T/pt unknown
- 2018-09-13 RS RS20210082A patent/RS61899B1/sr unknown
- 2018-09-13 SI SI201830344T patent/SI3736267T1/sl unknown
- 2018-09-13 UA UAA202002356A patent/UA125541C2/uk unknown
- 2018-09-13 PT PT187797980T patent/PT3681864T/pt unknown
- 2018-09-13 ES ES20183405T patent/ES2887449T3/es active Active
- 2018-09-13 HU HUE20183405A patent/HUE055050T2/hu unknown
- 2018-09-13 MX MX2020002806A patent/MX2020002806A/es unknown
- 2018-09-13 ES ES18779798T patent/ES2856751T3/es active Active
- 2018-09-13 LT LTEP20183405.8T patent/LT3736267T/lt unknown
- 2018-09-13 CA CA3074945A patent/CA3074945A1/en not_active Abandoned
- 2018-09-13 MD MDE20201159T patent/MD3736270T2/ro unknown
- 2018-09-13 PE PE2020000670A patent/PE20210140A1/es unknown
- 2018-09-13 RU RU2020113350A patent/RU2020113350A/ru unknown
- 2018-09-13 DK DK18779798.0T patent/DK3681864T3/da active
-
2020
- 2020-03-09 IL IL273163A patent/IL273163A/en unknown
- 2020-03-12 PH PH12020500509A patent/PH12020500509A1/en unknown
- 2020-03-13 CL CL2020000664A patent/CL2020000664A1/es unknown
- 2020-04-07 CO CONC2020/0004249A patent/CO2020004249A2/es unknown
- 2020-04-14 EC ECSENADI202021913A patent/ECSP20021913A/es unknown
- 2020-05-04 ZA ZA2020/02363A patent/ZA202002363B/en unknown
- 2020-05-19 US US16/878,416 patent/US10844041B2/en active Active
- 2020-05-19 US US16/878,430 patent/US10829473B2/en active Active
- 2020-05-19 US US16/878,421 patent/US10844042B2/en active Active
- 2020-05-19 US US16/878,468 patent/US10981890B2/en active Active
-
2021
- 2021-01-20 HR HRP20210099TT patent/HRP20210099T1/hr unknown
- 2021-01-28 CY CY20211100074T patent/CY1123761T1/el unknown
- 2021-04-15 US US17/231,482 patent/US20210238159A1/en not_active Abandoned
- 2021-07-26 HR HRP20211200TT patent/HRP20211200T1/hr unknown
- 2021-07-26 HR HRP20211198TT patent/HRP20211198T1/hr unknown
- 2021-08-03 CY CY20211100695T patent/CY1124615T1/el unknown
- 2021-08-04 CY CY20211100697T patent/CY1124401T1/el unknown
- 2021-09-27 JP JP2021156375A patent/JP7064073B2/ja active Active
- 2021-09-27 JP JP2021156376A patent/JP7064074B2/ja active Active
-
2022
- 2022-01-21 JP JP2022007648A patent/JP2022062093A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534360A5 (ja) | ||
| HRP20210099T1 (hr) | Modulatori proteina regulatora transmembranske vodljivosti kod cistične fibroze i postupci upotrebe | |
| CY1120903T1 (el) | Ενωσεις αμινοπυριδυλοξυπυραζολιου | |
| JP2017537066A5 (ja) | ||
| JP2016034978A5 (ja) | ||
| EA201201263A1 (ru) | Фармацевтическая композиция, содержащая этексилат дабигатрана | |
| JP2013014622A5 (ja) | ||
| MA38399B2 (fr) | Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique | |
| JP2014507446A5 (ja) | ||
| JP2015525757A5 (ja) | ||
| JP2014530840A5 (ja) | ||
| CY1115556T1 (el) | Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη | |
| RS54711B1 (en) | PARENTERAL TAPENTADOL ADMINISTRATION | |
| JP2018519259A5 (ja) | ||
| DK3866767T3 (da) | Farmaceutisk sammensætning til oral indgivelse omfattende aminopyrimidinderivat eller salt deraf | |
| JP2015509917A5 (ja) | ||
| JP2017513944A5 (ja) | ||
| WO2019004980A3 (en) | SOLID ORAL PHARMACEUTICAL COMPOSITIONS OF DABIGATRAN DEXILATE | |
| DK3802570T3 (da) | Forbedrede viruslignende nanopartikler til oral indgivelse | |
| JP2017014205A5 (ja) | ||
| EA201992644A1 (ru) | Твердые фармацевтические композиции на основе дабигатрана этексилата для перорального применения | |
| CN302322174S (zh) | 超声波焊头（z系统） | |
| CN302208234S (zh) | 牙刷板（728） | |
| CN302073115S (zh) | 空心矩形桩（h型） | |
| CN302073140S (zh) | 空心矩形桩（工字形） |